While discrepant results came from the addition of lenalidomide to R-CHOP in DLBCL [240,241], promising activity has been observed for triplet rituximab (anti-CD20), ibrutinib (BTKi) and lenalidomide [242,243] or in combination with rafasitamab (anti-CD19) for R/R DLBCL [244], reopening the door for this immunomodulatory drug to future clinical trials in combination [245], some of which currently involve PD-1/PD-L1 inhibitors [188]. This evidence concerns the gene CD274 and diffuse large B-cell lymphoma.